The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study.
 
Jeremy Aaron Ross
No Relationships to Disclose
 
Barrett Z. McCormick
No Relationships to Disclose
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Pavlos Msaouel
No Relationships to Disclose
 
Matthew T. Campbell
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
 
Amado J. Zurita
Honoraria - Janssen Oncology; Pfizer
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Amishi Yogesh Shah
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Surena F. Matin
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; Theracoat; Urogen pharma
Research Funding - AT&T
 
Christopher G. Wood
Honoraria - Pfizer
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Argos Therapeutics; Boehringer Ingelheim; GlaxoSmithKline; Ono Pharmaceutical; Pfizer
Travel, Accommodations, Expenses - Argos Therapeutics
 
Jose A. Karam
Honoraria - EMD Serono; Novartis; Pfizer
Consulting or Advisory Role - EMD Serono; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Padmanee Sharma
Stock and Other Ownership Interests - BioAtla; Constellation Pharmaceuticals; Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics
Consulting or Advisory Role - Amgen; Amgen (I); Astellas Pharma; AstraZeneca; AstraZeneca (I); BioAtla; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Merck Sharp & Dohme; Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer